Similar Papers

Paper Title
Journal
Date
Author
Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial
Pier Luigi Zinzani ...
Blood | VOL. 136
Pier Luigi Zinzani, et. al.Pier Luigi Zinzani ...
05 Nov 2020
The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
Steven M Horwitz ...
Blood | VOL. 136
Steven M Horwitz, et. al.Steven M Horwitz ...
05 Nov 2020
Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study
...
Blood | VOL. 138
, et. al. ...
05 Nov 2021
Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)
...
Blood | VOL. 136
, et. al. ...
05 Nov 2020
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Advances in RNA editing in hematopoiesis and associated malignancies.
Shuangshuang Pu ... Hui Cheng
Blood | VOL. -
Shuangshuang Pu, et. al.Shuangshuang Pu ... Hui Cheng
27 Jan 2025
Protection of β2GPI-Deficient Mice from Thrombosis Reflects a Defect in PAR3-facilitated Platelet Activation.
Paresh P Kulkarni ... Keith R Mccrae
Blood | VOL. -
Paresh P Kulkarni, et. al.Paresh P Kulkarni ... Keith R Mccrae
27 Jan 2025
Babesiosis and Sickle Red blood Cells: Loss of Deformability, Heightened Osmotic fragility, and Hypervesiculation.
Divya Beri ... Cheryl A Lobo
Blood | VOL. -
Divya Beri, et. al.Divya Beri ... Cheryl A Lobo
27 Jan 2025
Platelet activation and signaling in thrombus formation.
Frauke Swieringa ... Alice Assinger
Blood | VOL. -
Frauke Swieringa, et. al.Frauke Swieringa ... Alice Assinger
27 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.